Urease inhibitors for the treatment of H. pylori

Basit Öğe Kaydı
dc.authorscopusidAtilla Akdemir / 8912960500
dc.authorwosidAtilla Akdemir / G-2595-2015
dc.contributor.authorGüzel Akdemir, Özlen
dc.contributor.authorAkdemir, Atilla
dc.date.accessioned2025-04-16T20:04:24Z
dc.date.available2025-04-16T20:04:24Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü
dc.description.abstractIntroduction: Helicobacter pylori infects almost half of the World population. Although many infected people are symptom free, the microorganism can still cause a variety of gastrointestinal disorders and gastric adenocarcinoma. It is considered a priority pathogen for the development of new antibiotics by the World Health Organisation (WHO). Many virulence factors of H. pylori have been described. This paper will on H. pylori Urease (HPU). Area covered: This paper will discuss the (patho)physiology and structure of HPU. In addition, urease inhibitors with known activity against the HPU or inhibitors that show H. pylori growth inhibition will be discussed. Expert opinion: Increase in selectivity, affinity and potency of HPU inhibitors can be achieved by the design of compounds that interact with distinct regions within the enzyme active site. Especially, covalent interactions seem promising as they clearly effect the dose requirement of the drug candidate. © 2024 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.citationGüzel-Akdemir, Ö., & Akdemir, A. (2025). Urease inhibitors for the treatment of H. pylori. Expert Opinion on Therapeutic Patents, 35(1), 17-30.
dc.identifier.doi10.1080/13543776.2024.2423004
dc.identifier.endpage30
dc.identifier.issn13543776
dc.identifier.issue1
dc.identifier.scopusqualityQ1
dc.identifier.startpage17
dc.identifier.urihttp://dx.doi.org/10.1080/13543776.2024.2423004
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6065
dc.identifier.volume35
dc.identifier.wosWOS:001353174500001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorAkdemir, Atilla
dc.institutionauthoridAtilla Akdemir / 0000-0001-8416-0471
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofExpert Opinion on Therapeutic Patents
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAntibacterials
dc.subjectEnzyme İnhibitors
dc.subjectGrowth İnhibition
dc.subjectH. pylori
dc.subjectUrease Enzyme
dc.titleUrease inhibitors for the treatment of H. pylori
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Meslek Bilimleri Bölümü Diğer Yayınlar Koleksiyonu